Related Experiment Video
Updated: Oct 6, 2025

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
Published on: April 3, 2017
Elevated plasma macrophage migration inhibitor factor is associated with hypertension and hypertensive left
Ling Zhu1,2, Shasha Chen3, Na Liu4
1Department of Cardiology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, 710000, China.
Insights
Elevated macrophage migration inhibitor factor (MIF) is linked to hypertension and hypertensive left ventricular hypertrophy. Higher MIF levels significantly increase the risk of developing these cardiovascular conditions.
Area of Science:
- Cardiovascular Research
- Biomarkers
- Hypertension Research
Background:
- Macrophage migration inhibitor factor (MIF) is implicated in endothelial dysfunction and ventricular remodeling.
- Understanding MIF's role in hypertension and associated cardiac changes is crucial for cardiovascular health.
Purpose of the Study:
- To investigate the association between plasma MIF levels and the presence of hypertension.
- To explore the relationship between plasma MIF levels and hypertensive left ventricular hypertrophy (LVH).
Main Methods:
- A cohort of 308 participants, including 187 hypertensive patients and 121 healthy controls, was studied.
- Univariate and multivariate logistic regression models were used to assess associations.
- Correlation and receiver operating characteristic (ROC) analyses were performed.
Main Results:
- Elevated MIF levels were significantly associated with an increased risk of hypertension.
- Plasma MIF levels strongly correlated with hypertensive left ventricular mass index (r=0.580, P<0.001).
- Higher MIF levels were strongly associated with hypertensive LVH, with significant odds ratios (e.g., OR 24.95 for the highest tertile).
- ROC analysis showed MIF has good predictive accuracy for hypertensive LVH (AUC=0.84).
Conclusions:
- Elevated plasma macrophage migration inhibitor factor is a significant risk factor for hypertension.
- Increased MIF levels are closely associated with hypertensive left ventricular hypertrophy, suggesting its role as a potential biomarker.
Abstract:
Previous studies have found that the macrophage migration inhibitor factor is associated with endothelial dysfunction and ventricular remodelling. The aim of this study was to explore the potential relationship between plasma macrophage migration inhibitor factor levels and hypertension and hypertensive left ventricular hypertrophy. A total of 308 participants (including 187 uncomplicated hypertensive patients and 121 healthy controls) were enroled from 2017 to 2019. The association between macrophage migration inhibitor factors and hypertension and hypertensive left ventricular hypertrophy was estimated with univariate and multivariate logistic regression models. Elevated macrophage migration inhibitor factor was associated with the development of hypertension (second tertile: adjusted OR, 2.27, 95% CI, 1.24-4.16, P = 0.008; third tertile: adjusted OR, 5.43, 95% CI, 2.75-10.71, P < 0.001; compared with the first tertile). In addition, we assessed the association between macrophage migration inhibitor factor and left ventricular hypertrophy in hypertensive patients (n = 187). Plasma macrophage migration inhibitor factor was significantly correlated with hypertensive left ventricular mass index (r = 0.580, P < 0.001). In patients with hypertension, an elevated macrophage migration inhibitor factor was significantly associated with hypertensive left ventricular hypertrophy (second tertile: adjusted OR, 3.20, 95% CI, 1.17-8.78, P = 0.024; third tertile: adjusted OR, 24.95, 95% CI, 8.72-71.41, P < 0.001; compared with the first tertile). Receiver operating characteristic analysis indicated that macrophage migration inhibitor factor had reasonable predictive accuracy for the development of hypertensive left ventricular hypertrophy (area under curve 0.84, 95% CI 0.78-0.90, P < 0.001). Our data indicated that elevated macrophage migration inhibitor factor is associated with hypertension and hypertensive left ventricular hypertrophy.
More Related Videos
Related Concept Videos
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertension II: Pathophysiology

